BioCardia Presents at Alliance for Regenerative Medicine’s (ARM’s) Annual Cell & Gene Therapy Investor Day
April 18, 2018
SAN CARLOS, Calif. –BioCardia®, Inc. [OTC: BCDA], a leader in cardiovascular regenerative medicine, today announced that it was among the companies providing presentations at the Alliance for Regenerative Medicine’s (ARM’s) 6th Annual Cell & Gene Therapy Investor Day in New York City. Peter Altman, Ph.D., BioCardia President and CEO, presented a corporate overview at the conference.
ARM’s Cell & Gene Therapy Investor Day
A recording of the company’s presentation at the Cell & Gene Therapy Investor Day will be available at http://arminvestorday.com/webcast/.
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Company’s biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
David McClung, Chief Financial Officer
Cell & Gene
The Big Biz show
CALL US NOW
EMAIL US NOW